Development of a SARS-CoV-2 emerging variant infectivity and immune evasion panel to quantify the efficacy of vaccine booster induced neutralizing antibodies.
Department of Health and Human Services — Centers for Disease Control and Prevention
Opportunity #: R43IP001230-01
Description
SBIR Phase Phase I award: "Development of a SARS-CoV-2 emerging variant infectivity and immune evasion panel to quantify the efficacy of vaccine booster induced neutralizing antibodies." awarded to Virongy Biosciences, Inc. in Manassas, Virginia. Funded by Department of Health and Human Services (Centers for Disease Control and Prevention). Award amount: $273,181. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.gov